The International Classification of Diseases (ICD) and the Diagnostic and Statistical Manual (DSM) are routinely used in diagnosing illicit substance use disorders, but for people taking prescribed opioids they remain controversial. In pain medicine, the concept of "Addiction" is preferred with reduced emphasis on tolerance and withdrawal. This article examines the prevalence and characteristics of pharmaceutical opioid dependence/disorder according to ICD, DSM, and the pain medicine concept of "Addiction," among chronic noncancer pain (CNCP) patients prescribed opioids. In the current study, we used data from a national sample of 1134 people prescribed opioids for CNCP. Past 12-month "Addiction" (based on Pain Medicine definition), DSM, and ICD dependence definitions were assessed using the Composite International Diagnostic Interview. Twenty-four percent of the cohort met the criteria for "Addiction," 18% for DSM-5 use disorder and 19% for ICD-11 dependence. There was "substantial" concordance between "Addiction" and both DSM-5 use disorder and ICD-11 dependence, although concordance was much greater with ICD-11 dependence (kappa = 0.63 and 0.79, respectively). Participants meeting the criteria for "Addiction" only were older, less likely to engage in nonadherent behaviours, self-reported fewer problems or concerns with their medication, and had lower rates of psychological distress than those who also met the DSM-5 and ICD-11 criteria. The definition of "Addiction" captures a larger group of patients than other classification systems and includes people with fewer "risk" behaviours. Despite removal of tolerance and withdrawal for prescribed opioid use for DSM-5, we found that "Addiction" was more closely related to an ICD-11 diagnosis of pharmaceutical opioid dependence. Twenty-four percent of the cohort met criteria for 'Addiction', 18% for DSM-5 use disorder and 19%
Introduction
There has been increasing concern about risks for problematic use of pharmaceutical opioids in people prescribed opioids for chronic non-cancer pain (CNCP) [7] . Understanding the nature and extent of this issue has been limited due to inconsistency in how problematic opioid use is defined [28; 29; 36] . http://links.lww.com/PAIN/A251). In the field of pain medicine, however, they remain controversial [3; 29] ; tolerance and withdrawal are considered normal physiological consequences of long-term opioid use rather than indicators of problems. Other features are emphasised [21] .
'Addiction', as defined by the American Academy of Pain Medicine, American Pain Society and American Society of Addiction Medicine [28] is behaviour including one or more of the following, impaired control over drug use, compulsive use, continued use despite harm, and cravings. A recent consensus statement from the Analgesic, Anaesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) group [29] has supported and recommended this definition in patients who have been prescribed medication for pain [25] .
DSM-5 similarly specifies tolerance and withdrawal are not features of opioid use disorder in people taking opioids "solely under medical supervision" [2] .. In an earlier paper examining DSM vs ICD definitions, DSM-% did not agree well with DSM-IV, ICD-10 or ICD-11 (preliminary criteria) [11] . ICD-11 displayed the best model fit [11] . For a comparison of the features across the different classification systems see Table 1 .
Previous estimates of problematic opioid use in CNCP vary: 8-12% for 'addiction' [36] , DSM-5 lifetime pharmaceutical opioid use disorder ranged from 18.8% [11] to 41.3% [4] and lifetime ICD-11 opioid dependence 9.9% [11] . However, assessment methods varied across studies, from examining clinical notes to administering a structured, well-validated questionnaire.
There has been no contrast of ICD and DSM definitions and the pain medicine concept of 'Addiction' in a sample of patients prescribed opioids for CNCP. This paper uses data from a large, national, community cohort of people prescribed opioids for CNCP, to examine: 
Method

Study design and setting
The Pain and Opioid IN Treatment (POINT) study was designed to document patterns of pharmaceutical opioid use, and risk of adverse events and outcomes, in a prospective cohort of patients who were prescribed opioids for chronic non-cancer pain. The methodology of this cohort has been described in detail elsewhere [6] . The study was approved by the Human Research Ethics
Committee of UNSW Australia (HREC reference: # HC12149). The current study is based on data collected at the two-year time point. Included in the current paper is a sample of 1,134 participants who had completed the two-year interview and had been prescribed opioids in the preceding 12 months.
Eligibility criteria
At study enrolment POINT participants were: 18 years or older; taking opioids for CNCP for more than 6 weeks; competent in English; mentally and physically able to undertake telephone and selfcompletion interviews; without serious cognitive impairments; living with chronic non-cancer pain;
prescribed an opioid such as morphine, oxycodone or fentanyl (Schedule 8 in the Australian classification of 'drugs of dependence' and subject to additional regulatory controls regarding manufacture, supply, distribution, possession and use [32] . A history of injecting drug use was not an exclusion criterion, but those currently prescribed pharmaceutical opioids for opioid substitution therapy (OST) for heroin dependence or taking opioids for cancer pain were not eligible. Of the 2,091
participants assessed for eligibility, 90% (n=1873) were eligible and 1514 completed the baseline interview (n=201 refused after being deemed eligible and 100 were unable to be contacted). We had a completion rate of 82% (n=1,245) at the two-year time point; 113 participants have withdrawn over the two-years, 45 have died and 111 participants had discontinued pharmaceutical opioid use 12 months or more prior to interview.
Phone interviews were conducted by trained interviewers who had received training in the computer assisted personnel interviewing survey schedule. Interviewers had a minimum 3-year health or psychology degree, were trained in how to respond to reports of suicidal thoughts or suicidal plans, and were provided with glossaries of chronic pain medications and conditions.
The measures, tools, and domains collected were based on recommendations made under the auspices of the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) [13; 33] . The six core domains identified as being important in measuring core outcomes included pain, physical functioning, emotional functioning, participant ratings of improvement and satisfaction with treatments, symptoms and adverse events and participant disposition. Full details of the measures used in the study have been reported elsewhere [6] .
Assessment of DSM and ICD dependence and pharmaceutical opioid use disorders and 'Addiction'
Pharmaceutical opioid use disorders were assessed using the Composite International Diagnostic Interview 3.0 (CIDI) [15] . The CIDI has been used widely in epidemiological studies in many countries [12; 16; 26] , and has been shown to have excellent inter-rater reliability [15] , test-retest reliability [15] , and concordance with clinician diagnoses [14] . 'Addiction', and ICD and DSM diagnoses were determined from the CIDI responses. 'Addiction' and the criteria and the numbers of patients included in the various definitions are reported in [9] . Participants were asked for how long they had been in pain and from how many prescribers they had received their medication. Health service utilisation was defined as ever having surgery for pain, having been in a pain management course, or having seen a psychiatrist or psychologist.
The Short Form 12 (SF12) is a measure of general health functioning. It provides a physical and mental health component core and there are population norms, with a mean score of 50 and a SD of 10. In the current study, we only used the physical dimension. A cut-off of two standard deviations below the population mean was used to indicate severity in the current study.
Medications and problematic opioid use measures
Daily oral morphine equivalent (OME) doses for the pharmaceutical opioids taken by the cohort were estimated following review and synthesis of a range of clinical guidelines [22] . Current average daily dose (OME mgs/day) was calculated using opioid consumption from a one-week medication diary completed as part of the 2-year interview. OME were calculated for the 1,035 participants that reported past week opioid medication consumption.
The Prescribed Opioids Difficulty Scale (PODS) was used to measure participants' current problems and concerns about using prescribed opioids [31] . We used a continuous score on both the problems and the concerns domain on the PODS. The problems domain includes items such as "caused me to have difficulty remembering", "caused me to lose interest", and "caused me to feel depressed". The concern domain includes items such as preoccupation with medication, needing a higher dose, wanting to cut down, feeling dependent on medication and medication causing problems in work and social settings alert [31] .
The ORBIT is a 10-item measure of aberrant or non-adherent behaviours such as doctor shopping, diversion and other examples of unsanctioned use of medications. Each item is scored between zero to four to give a continuous score from 0-40 [19] .
Mental health and substance use
Depression and generalized anxiety disorder were measured by the PHQ-9 and GAD-7 modules of the Patient Health Questionnaire [17; 18] . Previously validated cut-offs were used as follows: moderate to severe depression was defined as a score of ≥ 10 on the PHQ-9 [17] and moderate to severe anxiety was defined as a score of ≥ 10 on the GAD-7 [30] .
A score of ≥ 3 on the Primary Care PTSD screen (PC-PTSD) was used to indicate PTSD [23] .
Participants were asked about lifetime and past 12 month alcohol and illicit drug use. Lifetime drug and alcohol use disorders (using ICD-10 dependence criteria) were assessed via the alcohol and drug use module of the Composite International Diagnostic Interview (CIDI) [37] .
The following questions on childhood maltreatment were asked, based on questions by Sansone [24] : "Before the age of 16, did you experience sexual abuse, physical abuse, emotional abuse, physical neglect, emotional and/or did you witness any violence." . In the current study only data from the sexual, physical and emotional abuse questions were used and were combined into one dichotomous variable of 'any childhood abuse'.
Data analysis
Analyses used STATA, version 12.0 (Stata Corporation, College Station, TX, USA). We reported the frequency of participants meeting each criterion for pharmaceutical opioid use disorder and dependence according to the five classification systems. We also examined the concordance between numbers of participants meeting criteria for each definition of disorder and concordance between each of the 'Addiction' criterion and the other diagnostic systems. Kappa, bias adjusted kappa (BAK), sensitivity, specificity and positive and negative predictive values are reported [20] to determine concordance between the 'Addiction' symptoms and the other classification systems.
Kappa interpretation was based those recommended by Viera and Garrett [35] , these were; less than 
Results
Of the participants, 57% were female (95% CI 54-60), the median age was 60 (IQR 51-69), 43% were unemployed (95%CI 40.0-46.2) and they had been prescribed opioids continuously for a median of 7 years (IQR 4-13). The most common pain conditions reported in the past 12 months were back and neck problems (85%, 95%CI 82.8-87. reported the presence of more than one pain condition in the preceding 12 months.
Twenty-five percent of the sample met criteria for physical dependence (as defined by withdrawal), and 13% met criteria for tolerance. Prevalence of problematic use differed depending on the classification system used ( Table 1 ). The prevalence of Dependence as defined by DSM-IV or ICD-10 was similar (8.4%, 95%CI 7.0-10.2 and 9.4%, 95%CI 7.8-11.2, respectively). Nineteen percent met ICD-11 criteria for Dependence, 18% met criteria for DSM-5 use disorder, and 24% met criteria for 'Addiction'. The relationship between ICD-11 and DSM-5 and 'Addiction' are presented in Figure 1 .
Table 1 and figure 1 here
Measures of concordance between the diagnostic systems are presented in Table 2 . There was moderate concordance between 'Addiction' and DSM-IV, ICD-10 dependence (kappa 0.46 and 0.48, respectively). There was substantial concordance between 'Addiction' and DSM-5 use disorder and ICD-11 dependence (kappa 0.63 and 0.79, respectively). None of the classification systems was shown to have excellent concordance with the definition of 'Addiction' Table 2 here
Measures of concordance between the individual criteria for 'Addiction' and corresponding criteria within each of the classification systems are presented in Table 3 . Impaired control was the most decisive criterion for 'Addiction' (PPV 1.00, NPV 0.95). The remaining three criteria showed lower specificity values and much lower bias-adjusted kappas (see Table 3 ). Amongst the other classification systems, given that each comprise polythetic symptom sets, there was only fair-tomoderate concordance between 'Addiction' criteria and DSM-IV and ICD-10 dependence, and DSM-5 use disorder. There was substantial concordance with impaired control and ICD-11 dependence (kappa 0.72), but only slight-to-fair concordance amongst the remaining three criteria. Table 3 here
Clinical and socio-demographic characteristics of the cohort who meet criteria for 'addiction', DSM-5
'use disorder' and ICD-11 'dependence' are presented in Table 4 and DSM-5 use disorder), were more likely to be male, younger, less likely to be in a married or defacto relationship, more likely to report more mental health problems, substance use histories,,, greater patient-centred problems, more aberrant or non-adherent medication behaviours associated with their opioid use, and a higher OME (Table 4 , column E).
No differences were identified between those who did not meet criteria for any dependence/use disorder (n=1043) and those who met criteria for 'Addiction' only (i.e. did not meet criteria for any other classification of 'dependence' or 'opioid use disorder' n=51, comparison not shown in Table 4 ).
Compared with those meeting criteria for DSM-5 'opioid use disorder' (n=202), participants who met criteria for 'addiction' only (i.e. those who met criteria for 'Addiction' and not DSM-5, n=202) ( Table   4 , column F), referred to as the 'Addiction' only group, were significantly less likely to report having engaged in non-adherent or aberrant behaviours in the preceding three months, less likely to report problems or concerns with their opioid use, less likely to suffer mental health problems or to have seen a mental health professional, or to have ever been in substance use treatment, and reported fewer side effects, pain interference, poor pain self-efficacy scores. Further, the 'Addiction' only group was also older and less likely to be unemployed, when compared with those who met criteria for opioid use disorder according to DSM-5.
Compared with those who met criteria for ICD-11 'opioid dependence' (n=213, Table 4 , column G), the 'Addiction' only group (i.e. those who met criteria for 'Addiction' only and not ICD-11 dependence, n=69) was significantly less likely to report aberrant behaviours, problems and concerns with their opioid use, but had more mental health problems and were more likely to have ever seen a health professional. They were also more likely to be older, in a married/defacto relationship and less likely to be unemployed or have completed year 10 of school education. Table 4 here
Discussion
There have been difficulties in determining rates of addiction/dependence in people prescribed opioids for pain, arising out of a lack of consistency in terminology and measures used [36] . This is the first study comparing pain medicine criteria for 'Addiction' with standard diagnostic criteria for Another controversial issue in the use of traditional classification systems in pain medicine is whether or not tolerance and withdrawal criteria should be included. In the current sample, 25.6% met criteria for physical dependence (i.e. withdrawal), and 14.2% met criteria for tolerance. It has been argued that the term dependence, according the ICD and DSM classifications, is confusing because it includes both physical and psychological dependence [28] . Current definitions of 'Addiction' among people prescribed long-term opioids for pain have not been empirically derived, although there has been a strong clinical consensus supporting the exclusion of the features of 'tolerance' and 'withdrawal' in identifying problematic use. Physical dependence is an expected response to prolonged exposure to opioids, and where a patient is prescribed opioids for a period of time, they may experience withdrawal symptoms when they cease. Psychological dependence, as used in the DSM and ICD [28] encompasses a broader behavioural syndrome, see (Table 1 ). The DSM-5 'opioid use disorder' classification attempted to address this issue by conditionally excluding tolerance and physical dependence criteria in patients who used opioid medications 'solely as prescribed', and these criteria were used in the current study.
The development of the 'addiction' classification in pain medicine arose out of a concern that too many individuals may be inappropriately diagnosed as 'dependent' according to the then DSM-IV or ICD-10, given theinclusion of withdrawal and tolerance in those diagnostic systems (Ballantyne et al).
It is of interest that while our study found 'substantial' concordance between 'Addiction' and DSM-5 use disorder and between 'addiction' and ICD-11 dependence, concordance was far greater for the latter. In a previous paper [11] , we found that DSM-5 had low concordance compared with other classifications (i.e. ICD-11, ICD-10, and DSM-IV). Criticisms of the DSM-5 suggest that the broader use of the term opioid use disorder, which encompasses both dependence and abuse criteria, does not equate to 'dependence'. It is unclear which particular patient group the DSM-5 now describes, but it appears to be different from those identified by ICD-10, by ICD-11, by DSM-IV dependence and by the pain medicine concept of 'Addiction'.
Of importance, the ICD and DSM classification systems were not designed specifically to address pharmaceutical drug use in patients using medications under medical supervision. The salience of concepts such as 'taking a substance in larger amounts or for longer than you intend to', 'wanting to cut down', or 'persistent use despite harms' are yet to be well understood from the perspective of the pain patient. This is especially challenging where medications have positives as well as negatives in the context of medical treatment, meaning motivations to continue or to cease medication may be unrelated to the construct of dependence, and is an important area for further work. Many such behaviours or cognitions (desire to cut down, prolonged use, use despite harms such as side effects) occur in patients taking medications for chronic conditions that are not CNS active, and hence may not necessarily signify dependence or addiction. This highlights that the current classification systems for dependence have been historically developed for substances such as alcohol and illicit drugs. This paper examines the best definitions available, but over time diagnostic criteria may be refined to better capture problems with medications used in a prescribed context.
Strengths and limitations-
This study used a large, national community sample of people prescribed opioids for CNCP to compare the performance of different diagnostic criteria. However, there is the potential that we did not succeed in recruiting a representative sample of people prescribed opioids for chronic pain. To investigate this possibility, additional data were collected from a random sample of pharmacies (n=71) on the characteristics of all their opioid customers seen during the six week recruitment window. This revealed reassuring similarities with our sample. Among the total number of customers recorded as purchasing opioids in these pharmacies, 52% were female (vs 55% in the POINT cohort);
and 7% were 18-34 years, 55% 35-64 years and 38% 65+ years (vs. 5%, 62% and 33% respectively, in the POINT cohort). Two thirds (63%) were prescribed oxycodone (vs. 62% in the POINT cohort), 16 .5% prescribed morphine (vs. 15% in the POINT cohort), and 24% prescribed buprenorphine patches (vs. 21% in the POINT cohort).
A further strength herein was that we measured medication nonadherence, unlike other studies that have examined the DSM-5 in people prescribed opioids for CNCP [4] . We were therefore able to determine which patients were using 'solely as prescribed' and so could apply the conditional exclusion of tolerance and withdrawal appropriately.
A limitation is the potential bias by reliance on self-report data. For instance, information on chronic medical illnesses and mental health problems were not verified through patient records, but the rates of pain conditions and findings were similar to those in previous research [5; 27] . Yet, all participants were informed that their responses would be de-identified and confidential, an assurance found to enhance the validity of self-reported substance use [10] . It is important to note that the current study was cross-sectional and future prospective studies, based on community samples, are necessary to determine which definitions of 'Addiction'/dependence are the most useful in identifying patients who encounter problems with their pharmaceutical opioid use. Finally, the definitions examined in this paper are based on information collected in an interview, rather than a diagnosis by a clinician; however, the CIDI has been found to be a reliable and valid method of diagnosing alcohol and substance use disorders [34] 
Conclusion
Although our study provides some empirical support for what has previously been based on clinical consensus, the 'addiction' concept used in pain medicine is broad and encompasses patients that may not be at high-risk of problematic opioid use. Even after applying conditional exclusion of tolerance and withdrawal, the DSM-5 pharmaceutical use disorder classification appears to capture a different patient group from those of other diagnostic systems. Patients identified by ICD-11 opioid dependence criteria were nearly all encompassed within the concept of 'addiction'. ICD-11 opioid dependence criteria seem to be the most promising in identifying those patients with CNCP who are experiencing significant problems in use, to inform their ongoing treatment planning. 11-3 .39)* ** includes meth/amphetamine, cannabis, cocaine, ecstasy, hallucinogenics, heroin. + from baseline interview + Did not meet criteria for DSM-IV ICD-10, ICD-11 dependence and DSM-5 opioid use disorder, # based on sample of 1,035. OME-Oral morphine equivalents, mg/day C A B AB ABC AC
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